Прием ингибиторов протонной помпы и прогноз пациентов после плановых чрескожных коронарных вмешательств
- Авторы: Комаров А.Л.1, Шахматова О.О.1, Мурасеева В.1, Новикова Е.С.1, Гуськова Е.В.2, Панченко Е.П.1
-
Учреждения:
- ФГБУ «Национальный медицинский исследовательский центр кардиологии» Минздрава России
- ФГБУ «Национальный медико-хирургический центр им. Н.И. Пирогова» Минздрава России
- Выпуск: Том 90, № 9 (2018)
- Страницы: 92-100
- Раздел: Передовая статья
- URL: https://journals.rcsi.science/0040-3660/article/view/32996
- DOI: https://doi.org/10.26442/terarkh201890992-100
- ID: 32996
Цитировать
Полный текст
Аннотация
Полный текст
Открыть статью на сайте журналаОб авторах
Андрей Леонидович Комаров
ФГБУ «Национальный медицинский исследовательский центр кардиологии» Минздрава Россиид.м.н., в.н.с. отд. клинических проблем атеротромбоза Москва, Россия
Ольга Олеговна Шахматова
ФГБУ «Национальный медицинский исследовательский центр кардиологии» Минздрава России
Email: Olga.shahmatova@gmail.com
к.м.н., м.н.с. отд. клинических проблем атеротромбоза Москва, Россия
Валерия Мурасеева
ФГБУ «Национальный медицинский исследовательский центр кардиологии» Минздрава Россииклинический ординатор Москва, Россия
Елена Степановна Новикова
ФГБУ «Национальный медицинский исследовательский центр кардиологии» Минздрава Россииаспирант отд. клинических проблем атеротромбоза Москва, Россия
Екатерина Владимировна Гуськова
ФГБУ «Национальный медико-хирургический центр им. Н.И. Пирогова» Минздрава Россиик.м.н., врач-кардиолог Москва, Россия
Елизавета Павловна Панченко
ФГБУ «Национальный медицинский исследовательский центр кардиологии» Минздрава Россиид.м.н., проф., руководитель отд. клинических проблем атеротромбоза Москва, Россия
Список литературы
- Valgimigli M, Bueno H, Byrne R, et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. Europ J Cardio-Thoracic Surgery. 2017;53(1):34-78. doi: 10.1093/ejcts/ezx334
- Steffel J, Verhamme P, Potpara T, et al. The 2018 European Heart Rhythm Association Practical Guide on the use of non - vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J. 2018;39(16):1330-193. doi: 10.1093/eurheartj/ehy136
- Harjai K, Shenoy C, Orshaw P, Usmani S, Boura J, Mehta R. Clinical Outcomes in Patients With the Concomitant Use of Clopidogrel and Proton Pump Inhibitors After Percutaneous Coronary Intervention: An Analysis From the Guthrie Health Off-Label Stent (GHOST) Investigators. Circulation: Cardiovascular Interventions. 2011;4(2):162-70. doi: 10.1161/circinterventions.110.958884
- Juurlink D, Gomes T, Ko D, et al. A population - based study of the drug interaction between proton pump inhibitors and clopidogrel. Can Med Assoc J. 2009;180(7):713-18. doi: 10.1503/cmaj.082001
- Schmidt M, Johansen M, Robertson D, et al. Concomitant use of clopidogrel and proton pump inhibitors is not associated with major adverse cardiovascular events following coronary stent implantation. Aliment Pharmacol Ther. 2011;35(1):165-74. doi: 10.1111/j.1365-2036.2011. 04890.x
- Simon T, Steg P, Gilard M, et al. Clinical Events as a Function of Proton Pump Inhibitor Use, Clopidogrel Use, and Cytochrome P450 2C19 Genotype in a Large Nationwide Cohort of Acute Myocardial Infarction: Results From the French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) Registry. Circulation. 2011;123(5):474-82. doi: 10.1161/circulationaha.110.965640
- van Boxel O, van Oijen M, Hagenaars M, Smout A, Siersema P. Cardiovascular and Gastrointestinal Outcomes in Clopidogrel Users on Proton Pump Inhibitors: Results of a Large Dutch Cohort Study. Am J Gastroenterol. 2010;105(11):2430-36. doi: 10.1038/ajg.2010.334
- Charlot M, Ahlehoff O, Jorgensen C, et al. Proton pump inhibitors are associated with cardiovascular risk independent of clopidogrel use in patients with myocardial infarction: a nationwide propensity score matched study. J Am Coll Cardiol. 2010;55(10):A108.E1005. doi: 10.1016/s0735-1097(10)61006-6
- Schmidt M, Johansen M, Robertson D, et al. Concomitant use of clopidogrel and proton pump inhibitors is not associated with major adverse cardiovascular events following coronary stent implantation. Aliment Pharmacol Ther. 2011;35(1):165-74. doi: 10.1111/j.1365-2036.2011. 04890.x
- Valkhoff V,‘t Jong G, Van Soest E, Kuipers E, Sturkenboom M. Risk of recurrent myocardial infarction with the concomitant use of clopidogrel and proton pump inhibitors. Aliment Pharmacol Ther. 2010;33(1):77-88. doi: 10.1111/j.1365-2036.2010.04485.x
- Cardoso R, Benjo A, Di-Nicolantonio J, et al. Incidence of cardiovascular events and gastrointestinal bleeding in patients receiving clopidogrel with and without proton pump inhibitors: an updated meta - analysis. Open Heart. 2015;2(1):e000248. doi: 10.1136/openhrt-2015-000248
- Wedemeyer R, Blume H. Pharmacokinetic Drug Interaction Profiles of Proton Pump Inhibitors: An Update. Drug Saf. 2014;37(4):201-11. doi: 10.1007/s40264-014-0144-0
- Angiolillo D, Gibson C, Cheng S, et al. Differential Effects of Omeprazole and Pantoprazole on the Pharmacodynamics and Pharmacokinetics of Clopidogrel in Healthy Subjects: Randomized, Placebo-Controlled, Crossover Comparison Studies. Clinical Pharmacology & Therapeutics. 2010;89(1):65-74. doi: 10.1038/clpt.2010.219
- Hokimoto S, Mizobe M, Akasaka T, et al. Impact of CYP2C19 Polymorphism and Proton Pump Inhibitors on Platelet Reactivity to Clopidogrel and Clinical Outcomes Following Stent Implantation. Thromb Res. 2014;133(4):599-605. doi: 10.1016/j.thromres.2014.01.003
- Frelinger A, Lee R, Mulford D, et al. A Randomized, 2-Period, Crossover Design Study to Assess the Effects of Dexlansoprazole, Lansoprazole, Esomeprazole, and Omeprazole on the Steady-State Pharmacokinetics and Pharmacodynamics of Clopidogrel in Healthy Volunteers. J Am Coll Cardiol. 2012;59(14):1304-11. doi:10.1016/j. jacc.2011.12.024
- Information for Healthcare Professionals: Update to the labeling of Clopidogrel Bisulfate (marketed as Plavix) to alert healthcare professionals about a drug interaction with omeprazole (marketed as Prilosec and Prilosec OTC) [Ссылка доступна на 23.05.2018];2009 http://www.pdr.net/fda-drug-safety-communication/plavix?druglabelid= 525&id=5033
- Sherwood M.W, Melloni C, Jones W.S, et al. Individual proton pump inhibitors and outcomes in patients with coronary artery disease on dual antiplatelet therapy: a systematic review. J Am Heart Assoc. 2015;4(11):e002245. doi: 10.1161/JAHA.115.002245
- Pello Lázaro A, Cristóbal C, Franco-Peláez J, et al. Use of Proton-Pump Inhibitors Predicts Heart Failure and Death in Patients with Coronary Artery Disease. PLoS ONE. 2017;12(1):e0169826. doi:10. 1371/journal.pone.0169826
- Bhatt D.L, Cryer B.L, Contant C.F, et al. Clopidogrel with or without Omeprazole in Coronary Disease. New England J Medicine. 2011; 364(7):681-83. doi: 10.1056/nejmc1013859
- Hsu P, Lai K, Liu C. Esomeprazole With Clopidogrel Reduces Peptic Ulcer Recurrence, Compared With Clopidogrel Alone, in Patients With Atherosclerosis. Gastroenterology. 2011;140(3):791-8.e2. doi: 10.1053/j.gastro.2010.11.056
- Hsu P. Proton Pump Inhibitor Prevents Clinically Significant Upper Gastrointestinal Evetns in Clopidogrel Users With Ulcer History. Gastroenterology. 2012;142(5):S-27. doi: 10.1016/s0016-5085(12)60109-7
- Vaduganathan M, Cannon C, Cryer B, et al. Efficacy and Safety of Proton-Pump Inhibitors in High-Risk Cardiovascular Subsets of the COGENT Trial. Am J Med. 2016;129(9):1002-5. doi: 10.1016/j.amjmed. 2016.03.042
- Bhurke S, Martin B, Li C, Franks A, Bursac Z, Said Q. Effect of the Clopidogrel-Proton Pump Inhibitor Drug Interaction on Adverse Cardiovascular Events in Patients with Acute Coronary Syndrome. Pharmacotherapy: J Human Pharmacology and Drug Therapy. 2012; 32(9):809-18. doi: 10.1002/j.1875-9114.2012.01112.x
- Chandrasekhar J, Bansilal S, Baber U, et al. Impact of proton pump inhibitors and dual antiplatelet therapy cessation on outcomes following percutaneous coronary intervention: Results From the PARIS Registry. Catheterization and Cardiovascular Interventions. 2016;89(7):E217-E225. doi: 10.1002/ccd.26716
- Комаров А.Л. Факторы, определяющие прогноз и эффективность антитромбоцитарной терапии у больных хронической ишемической болезнью сердца. Дисс.. М., 2013. Доступно по: http://cardioweb.ru/files/autoref/%D0%B0%D0%B2%D1%82%D0%BE%D1 %80%D0%B5%D1%84%D0%B5%D1%80%D0%B0%D1%82%20 %D0%B4%D0%BC%D0%BD%20%D0%9A%D0%BE%D0%BC% D0%B0%D1%80%D0%BE%D0%B2%20%D0%90.%D0%9B.pdf. Ссылка активна на 23.05.2018
- Sukhovershin R.A, Cooke J.P. How may proton pump inhibitors impair cardiovascular health? Amer J Cardiovascular drugs : drugs, devices, and other interventions. 2016;16(3):153-61. doi: 10.1007/s40256-016-0160-9
- Goodman S, Clare R, Pieper K, et al. Association of Proton Pump Inhibitor Use on Cardiovascular Outcomes With Clopidogrel and Ticagrelor: Insights From the Platelet Inhibition and Patient Outcomes Trial. Circulation. 2012;125(8):978-86. doi: 10.1161/circulationaha.111. 032912
- Shah N, Le Pendu P, Bauer-Mehren A, et al. Proton Pump Inhibitor Usage and the Risk of Myocardial Infarction in the General Population. PLoS ONE. 2015;10(6):e0124653. doi: 10.1371/journal.pone.0124653
- Ghebremariam Y, Le Pendu P, Lee J, et al. Unexpected Effect of Proton Pump Inhibitors: Elevation of the Cardiovascular Risk Factor Asymmetric Dimethylarginine. Circulation. 2013;128(8):845-53. doi:10.1161/ circulationaha.113.003602
- Mc Coll K. Effect of Proton Pump Inhibitors on Vitamins and Iron. Am J Gastroenterol. 2009;104(S2):S5-S9. doi: 10.1038/ajg.2009.45
- Toh J, Ong E, Wilson R. Hypomagnesaemia associated with long - term use of proton pump inhibitors. Gastroenterol Rep (Oxf). 2014;3(3): 243-53. doi: 10.1093/gastro/gou054
- Dial M. Proton Pump Inhibitor Use and Enteric Infections. Am J Gastroenterol. 2009;104(S2):S10-S16. doi: 10.1038/ajg.2009.46
- Eom C, Jeon C, Lim J, Cho E, Park S, Lee K. Use of acid - suppressive drugs and risk of pneumonia: a systematic review and meta - analysis. Can Med Assoc J. 2010;183(3):310-9. doi: 10.1503/cmaj.092129
- Bosch J, Eikelboom J, Connolly S, et al. Rationale, Design and Baseline Characteristics of Participants in the C ardiovascular O utco m es for P eople Using A nticoagulation S trategie s (COMPASS) Trial. Canadian J Cardiol. 2017;33(8):1027-35. doi: 10.1016/j.cjca. 2017.06.001